...ARRS completed its acquisition of Khepri for 2.3 million ARRS common shares (see BioCentury Nov. 13... ...quarter for in-process R&D and acquisition costs. Arris Pharmaceutical Corp. (ARRS), South San Francisco, Calif. Khepri Pharmaceuticals Inc....
...The South San Francisco company created Khepri Canada, a Montreal research hub focused on therapeutics based... ...focused on therapeutics based on proteases and protease inhibitors. Of the initial $7 million financing, Khepri... ...25 percent stake, respectively. Innovatech is a parapublic agency that operates as a venture fund. Khepri Pharmaceuticals Inc.
WIR...
...ARRS completed its acquisition of Khepri for 2.3 million ARRS common shares (see BioCentury Nov. 13... ...quarter for in-process R&D and acquisition costs. Arris Pharmaceutical Corp. (ARRS), South San Francisco, Calif. Khepri Pharmaceuticals Inc....
...The South San Francisco company created Khepri Canada, a Montreal research hub focused on therapeutics based... ...focused on therapeutics based on proteases and protease inhibitors. Of the initial $7 million financing, Khepri... ...25 percent stake, respectively. Innovatech is a parapublic agency that operates as a venture fund. Khepri Pharmaceuticals Inc.
WIR...